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Abstract  24 
Improved nitrogen utilization in cattle is important in order to secure a sustainable cattle production. 25 
As purines and pyrimidines (PP) constitute an appreciable part of rumen nitrogen, an improved 26 
understanding of the absorption and intermediary metabolism of PP is essential. The present work 27 
describes the development and validation of a sensitive and specific method for simultaneous 28 
determination of 20 purines (adenine, guanine, guanosine, inosine, 2’-deoxyguanosine, 2’-29 
deoxyinosine, xanthine, hypoxanthine), pyrimidines (cytosine, thymine, uracil, cytidine, uridine, 30 
thymidine, 2’-deoxyuridine), and their degradation products (uric acid, allantoin, β-alanine, β-31 
ureidopropionic acid, β-aminoisobutyric acid) in blood plasma of dairy cows. The high performance 32 
liquid chromatography-based technique coupled to electrospray ionization tandem mass 33 
spectrometry (LC- MS/MS) was combined with individual matrix-matched calibration standards 34 
and stable isotopically-labelled reference compounds. The quantitative analysis was preceded by a 35 
novel pre-treatment procedure consisting of ethanol precipitation, filtration, evaporation and 36 
reconstitution. Parameters for separation and detection during the LC-MS/MS analysis were 37 
investigated. It was confirmed that using a log-calibration model rather than a linear calibration 38 
model resulted in lower CV% and a lack of fit test demonstrated a satisfying linear regression. The 39 
method covers concentration ranges for each metabolite according to that in actual samples e.g. 40 
guanine: 0.10-5.0 µmol/L, and allantoin: 120-500 µmol/L. The CV% for the chosen quantification 41 
ranges were below 25%. The method has good repeatability (CV% ≤25%) and intermediate 42 
precision (CV% ≤25%) and excellent recoveries (91-107%). All metabolites demonstrated good 43 
long-term stability and good stability within-runs (CV%≤10%). Different degrees of absolute 44 
matrix effects were observed in plasma, urine and milk. The determination of relative matrix effects 45 
revealed that the method was suitable for almost all examined PP metabolites in plasma drawn from 46 
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an artery and the portal hepatic, hepatic and gastrosplenic veins and, with a few exceptions, also for 47 
other species such as chicken, pig, mink, human and rat.  48 
Key words: Nitrogen; Ruminant; Purine; Pyrimidine; Plasma, LC-MS/MS. 49 
1. Introduction  50 
The global efficiency of nitrogen in animal production is only slightly over 10%, with the result that 51 
102 Tg (1012 gram) nitrogen is excreted annually (1998 figures) by domesticated animals globally 52 
[1]. The nitrogen efficiency in dairy cows is generally low [2], and not only the environment, but 53 
also the productive efficiency, would benefit from an optimization of diet and metabolism to 54 
improve nitrogen efficiency and utilization [1, 3, 4]. Most research hitherto has focused on refining 55 
protein and amino acid utilization, but this has only led to minor improvements in efficiency [4-6]. 56 
A better understanding of the quantitative absorption and intermediary metabolism of other 57 
nitrogenous products such as the purines and pyrimidines (PP), the building blocks of nucleic acids 58 
and main constituents of DNA/RNA, could uncover new ways of improving dairy cow nitrogen 59 
use-efficiency and propose new feeding strategies [7, 8]. So far, the possible significance of 60 
microbial PP in the nutritional physiology of ruminants has not been investigated, regardless of the 61 
fact that they correspond to more than 20% of the total microbial nitrogen supply [7-9]. Little is 62 
known about the quantitative aspects of PP metabolism. What is known, however, is that the 63 
purines go through an effective multistep degradation to uric acid and allantoin, and the pyrimidines 64 
are similarly degraded to β-alanine, before excretion [8, 10]. 65 
Quantitative analysis of PP in dairy cattle research has almost solely focused on purines in urine, as 66 
excretion of purine derivatives can be used as an indirect measure of rumen microbial synthesis [11-67 
14]. Most published methods have thus been developed for purine metabolites in urine. Only 68 
recently, Boudra et al. (2012) published a method able to quantify the pyrimidine degradation 69 
products (DP) β-alanine and β-aminoisobutyric acid as well [14].  70 
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Different analytical separation methods have been used for determining PP in biological matrices of 71 
which the majority has applied high performance liquid chromatography (HPLC) [15-17] or 72 
capillary electrophoresis chromatography [17-20]. When high separation selectivity and sensitivity 73 
were essential, electrokinetic techniques [16] or ultra high performance liquid chromatography [21] 74 
have been used. Concerning detection, spectrometric, electrochemical or mass spectrophotometric 75 
detection methods have been used, with ultra violet detection coupled to HPLC being the most 76 
common one [15-17]. HPLC coupled with tandem spectrometric detection (LC-MS/MS) is 77 
currently considered the method of choice for quantitative analysis of compounds in biological 78 
matrices [22] and LC-MS/MS has been shown to be capable of quantifying PP and their derivatives 79 
accurately in urine. 80 
For this study, we wanted to develop and validate an LC-MS/MS method for quantification of a 81 
range of PP and their derivatives in cow blood plasma. Into this procedure, we wanted to 82 
incorporate matrix-matched calibration standards as well as stable isotopically-labelled reference 83 
compounds (SIL).  As no appropriate pre-treatment procedure was identified in the literature, we 84 
also wanted to develop a good, stable, simple, component-specific, and repeatable pre-treatment 85 
protocol for the plasma samples.  86 
Several sets of plasma samples from experiments that attempted to manipulate urea-recycling and 87 
increase nitrogen utilization using multicatheterized Danish Holstein cows were employed in the 88 
development of this method [23] because these were representative of the types of samples that this 89 
method is likely to be used for in the future.  90 
 91 
2. Materials and Methods  92 
2.1 Chemicals, reagents and materials 93 
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Water quality was at all times secured by treatment on a Millipore Synergy® UV water treatment 94 
system from Millipore A.S. (Molsheim, France). Methanol (MeOH) from Poch S.A. (Gliwice, 95 
Poland) and ethanol (EtOH 99.9% vol.) from Kemetyl A/S (Køge, Denmark) were of HPLC grade. 96 
Formic acid (98-100%) (HCOOH), acetic acid (100%) (CH3COOH), and ammonium solution 97 
(25%) (NH4OH) from Merck (Darmstadt, Germany) were of analytical reagent grade. Sodium 98 
hydroxide (NaOH), also from Merck, was prepared in a 0.01 M aqueous solution. Tricholoroacetic 99 
acid (≥99.0%) from Sigma-Aldrich (Brøndby, Denmark) was prepared in a 12% v/v aqueous 100 
solution (TCA) daily. Contamination between samples was minimized by the use of disposable 101 
materials (vials, bottles etc.) where practicable, or through the use of lab equipment that was 102 
cleaned without the use of detergents.  103 
 104 
2.2 Standards  105 
The following compound standards (bases (BS), nucleosides (NS), DP) were obtained from Sigma-106 
Aldrich (Brøndby, Denmark): adenine, guanine, cytosine, thymine, uracil, adenosine, guanosine, 107 
cytidine, uridine, inosine, 2’-deoxyadenosine, 2’-deoxyguanosine, 2’-deoxycytidine, thymidine, 2’-108 
deoxyuridine, 2’-deoxyinosine, xanthine, hypoxanthine, uric acid, allantoin, β-alanine, β-109 
ureidopropionic acid and β-aminoisobutyric acid. β-ureidoisobutyric acid, one important 110 
intermediate pyrimidine derivate metabolite, was not commercially available and could not be 111 
included. No traces of either adenosine or 2’-deoxyadenosine were identified during method 112 
development in plasma or urine samples. 2’-deoxycytidine was present in trace amounts but even 113 
after extensive optimization the sensitivity remained too low for quantification. These three 114 
components were therefore not pursued further. The chemical structures of the targeted metabolites 115 
are shown in Table 1.  116 
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Stable isotopically-labelled reference compounds used as internal standards were purchased from 117 
Cambridge Isotope Laboratories (Andover, USA).  These were: adenine (8-13C), guanine (8-118 
13C;7,9-15N2), thymine (15N2), uracil (U-13C4;U-15N2), guanosine (U-13C10;U-15N5),  inosine (U-119 
15N4), cytidine (U-13C9;U-15N3), uridine (U-13C9;U-15N2), 2'-deoxyguanosine (U-15N5), thymidine 120 
(U-15N2), xanthine (1,3-15N2), hypoxanthine (15N4), uric acid (1,3-15N2), and β-alanine (U-121 
13C3;15N). Cytosine (2,4-13C2;15N3) was purchased from Sigma-Aldrich (Brøndby, Denmark). All 122 
were 13C and/or 15N labelled with purities of at least 95% (95-99%). Unfortunately, exact SIL were 123 
not available for all metabolites studied; a suitable SIL was consequently selected on its similarity 124 
to the corresponding metabolite in terms of structure, retention time, fragmentation pattern and 125 
group. Individual stock solutions of all compound standards and SIL were prepared and kept at -126 
80°C. Bases and purine DP were diluted in water and NS and pyrimidine DP were diluted in 0.01 M 127 
NaOH solution. Two stock concentrations of 500 and 5,000 µmol/L were made for each compound 128 
standard. The exception was for uric acid and allantoin, where the stock concentration was 129 
500/2,000 µmol/L and 500/40,000 µmol/L, respectively. For SIL only the low concentration stock 130 
was prepared. All stocks were filtered through 0.45 µm PALL GHP Membrane syringe filters 131 
purchased from VWR (Herlev, Denmark) and kept at -20°C in dark vials. Appropriate dilutions of 132 
these solutions were made in water to produce standard mixtures and SIL mixtures for external 133 
calibration and quantification.  134 
 135 
Table 1  136 
 137 
2.3 Samples  138 
A number of 5 ml aliquots of heparinized plasma to be used for external calibration and quality 139 
control were prepared from two liters of venous blood [23] drawn from a Danish Holstein dairy cow 140 
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fed a traditional total mixed ration. Experimental plasma samples were obtained from a feeding 141 
experiment [24] with multicatheterized dairy cows [25,26]. This set of samples was drawn from 142 
four blood vessels simultaneously, representing blood from an artery and the portal hepatic, hepatic 143 
and gastrosplenic veins. Additional test plasma samples were obtained on site for relative matrix 144 
effect evaluations. These samples were from five other species (chicken, pig, mink, human, and rat) 145 
for between species comparisons, four multicatheterized cows (jugular vein) for intraspecies 146 
comparisons, and bovine urine and milk samples for matrix effect evaluations.  147 
 148 
2.4 Pre-treatment  149 
Before pre-treatment, plasma samples for quantification of uric acid and uracil were diluted twenty-150 
fold (5% v/v) and four-fold (25% v/v) in water, respectively. This was, in the case of uric acid, to 151 
avoid a non-linear calibration curve with the very high uric acid concentrations in all samples, and, 152 
in the case of uracil, to be able to distinguish the small uracil signal from the pronounced 153 
background noise. Pre-treatment: Plasma samples were defrosted and immediately put on ice. The 154 
sample (300 µL) was then added to a SIL mixture and a water/standard mixture (550 µL total vol.) 155 
before being precipitated with 1.8 mL ice-cold ethanol (10 min., on ice, -20°C). This was followed 156 
by centrifugation (15 min., 5,500 × g, 4°C). The supernatant was ultrafiltered on a Pall Nanosep 157 
10K, Omega membrane spin filter purchased from VWR. A 500 µL aliquot of filtered supernatant 158 
was dried down under a flow of nitrogen on a SuperthermTM fitted with a Mini Oven for AI blocks 159 
and evaporator with valves from Mikrolab A/S (Aarhus, Denmark) in conical autosampler vials 160 
from VWR until dryness (app. 75 min., room temp.). The pellet was re-suspended in 100 µL cold 161 
solvent (A) (30 min., 4°C) and transferred to a clean dark LC-vial. Matrix-matched external 162 
calibrators were treated similarly to standard plasma. Milk samples were cleared with ice-cold TCA 163 
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12% (end 50% v/v) before pre-treatment. Urine samples were handled as plasma samples 164 
throughout.  165 
 166 
2.5 LC-MS/MS analysis  167 
Chromatographic separation was performed on an Agilent 1100 series HPLC system (Agilent 168 
Technologies, Hørsholm, Denmark) with a Synergi™ Hydro-RP LC Column (250 mm × 2 mm, 4 169 
µm) protected by a conventional guard column of the same material purchased from Phenomenex 170 
(Værløse, Denmark). Samples were analyzed in five separate runs, three in negative electrospray 171 
(ESI) mode and two in positive ESI mode. The five groups of metabolites and their 172 
chromatographic profiles are shown in Table 2. Separation was performed using a gradient solvent 173 
system. For each run, HPLC solvents were freshly prepared and cleared on a 0.45 µm Pall 174 
hydrophilic polypropylene membrane filter purchased from VWR. Both solvents (A) and (B) were 175 
prepared from a 0.05 mol/L acetic acid buffer containing 10% or 50% methanol, respectively. The 176 
acetic acid buffer was prepared by adjusting 0.05 mol/L acetic acid to pH 4.0 with ammonium 177 
solution and readjusting to pH 2.8 with formic acid. The following elution gradient was used: initial 178 
percentage of solvent B was 5%, this was raised to 100% in 8 min and kept there for 6 min, then 179 
lowered to 5% in 30 sec, after which it was kept constant for 3.5 min to re-equilibrate the column 180 
prior to the next injection. The flow rate was 200 µL/min and the injection volume was 5 µL. The 181 
column temperature was maintained at 30°C while the auto sampler temperature was set to 4°C to 182 
stabilize the samples during time-consuming analyses. The total run time was 18 min per sample.  183 
 184 
Table 2 185 
 186 
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A Waters (Hedehusene, Denmark) micromass triple quadropole mass spectrometer was used for 187 
electrospray mass spectrometric analyses using massLynx 4.0 (Waters) software for data collection 188 
and processing. Capillary voltage was set to 3.2 kV, source temperature to 120°C, and desolvation 189 
temperature to 400°C. The cone and desolvation gas flows (nitrogen and argon) were set at 29 and 190 
628 L/hour, respectively. Fragment ion spectra were recorded in both polarities and promising 191 
selective fragment ions were tested and optimized along with the cone voltage in multiple-reaction 192 
monitoring (MRM) mode. The values of the tune parameters were optimized by separately infusing 193 
a solution (500 µmol/L) of each metabolite in its mobile phase at a flow rate of 10 µL/min. The 194 
MRM transitions and the applied cone voltages and collision energies are summarized in Table 3. 195 
Common transitions were originated from the loss of HCN, NH3, ribose, deoxyribose, HNCO, 196 
HNCONH2 and H2O fragments for the various PP metabolites (Table 1). The most intense 197 
transition reaction was used for quantification (Table 3). Data were collected in centroid mode with 198 
a constant dwell time of 0.05 sec and an interscan delay of 0.02 sec. 199 
 200 
Table 3  201 
 202 
2.6 Calibration and quantification  203 
Quantification was performed by matrix-matched external calibration applying standard plasma 204 
spiked with a two-fold serial dilution of mixed standard solutions to obtain seven different 205 
concentration levels of each compound. The only exception was with uracil where a two-third-fold 206 
serial dilution was applied. Standard plasma (not spiked) was used for subtraction and quality 207 
control but was not included in the regression analysis. In general, all samples and calibrators were 208 
analyzed in duplicate and a standard curve and quality control samples were analyzed at the 209 
beginning and at the end of each sequence. The response was calculated as the chromatographic 210 
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peak area for all compounds. When applying standard plasma, which contained unknown quantities 211 
of the metabolites under investigation, the measured metabolite response was initially normalized 212 
and the response from the standard plasma was subtracted. The mean of the measured SIL 213 
responses/SIL area for each sample was used as the normalization factor. During method 214 
development the focus of work was on quantifying as low concentrations of metabolite as possible. 215 
Matrix-matched calibration curves, within the relevant concentration ranges given in Table 4, were 216 
generated for each metabolite at four (allantoin) or seven concentration levels on five consecutive 217 
days for determining and evaluating the calibration model. As noted previously, uric acid and uracil 218 
were quantified from diluted samples. The coefficient of variation (CV%) for each concentrate level 219 
was then calculated for a logarithmic and a linear calibration model to test the use of log-log 220 
transformation. The linearity of the log calibration curves were studied with a lack of fit hypothesis 221 
test. Subsequently, the homogeneity of variance was estimated for each concentration by plotting 222 
the CV% against log(concentration) and the quantification range set to the lowest and highest 223 
quantified concentration giving a CV% below 25%.  224 
 225 
Table 4 226 
 227 
2.7 Validation procedure  228 
The method was validated according to reports from the “Analytical methods validation: 229 
bioavailability, bioequivalence and pharmacokinetic studies” conferences held in Washington in 230 
1990 [27] and 2000 [28], as described by Peters et al. [29]. It was validated with respect to 231 
assessment of selectivity, stability, precision, recovery, and matrix effect. 232 
Selectivity: Metabolite and SIL cross-talk was evaluated by analyzing the standard compounds 233 
alone and together with their corresponding SIL (no blank matrix was available). Three groups were 234 
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studied and their signals compared; a compound standard group (10% v/v, 50 µmol/L), a SIL group 235 
(10% v/v, 50 µmol/L), and a combined group (5% v/v, 25 µmol/L). Analyses of BS/DP and NS 236 
were carried out separately.  237 
Stability: For continuous evaluation of long-term storage stability, a fresh quality control sample 238 
was analyzed in all analytical runs. The stability within runs (6-24 h) was evaluated in two ways. 239 
First, a quality control sample was analyzed at the beginning and at the end of each sequence (data 240 
not shown). Secondly, a set of spiked standard plasma samples were analyzed at five different times 241 
(different vials) during a 30 hour sequence. Analysis of variance (ANOVA) using linear mixed 242 
models procedures  was used to test the stability over time, both with a trend element and with 243 
random changes over and above the linear trend (regression line) [30,31]. Applying ANOVA, the 244 
across-day variation of the PP calibration curves (intercepts and slopes as interactions with test day) 245 
was assessed over five consecutive days and expressed by their P-values. The stability during 246 
repeated freeze-thaw cycles was not explored since all plasma samples in the present study were 247 
only thawed once.  248 
Precision and recovery: Precision of the method, in terms of within-day variation (repeatability) 249 
and across-day variation (intermediate precision), was determined by analyzing replicate sets of 250 
spiked standard plasma samples on five separate days expressed as their CV%. The absolute 251 
recoveries were calculated using the same set of spiked standard plasma, at one level, by comparing 252 
the obtained concentrations with the initial spiked level.  253 
Matrix effect: Early tests with spiked water, urine and plasma samples revealed large variations in 254 
matrix effect-induced signal suppression and enhancement between the metabolites included in the 255 
analysis. Following optimization of the pre-treatment procedure, these matrix effects were 256 
evaluated as the difference between samples of water and standard plasma, urine or milk samples 257 
spiked with constant amounts of SIL before pre-treatment. Thus, we took advantage of the fact that 258 
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the incorporated SIL should behave as their matching metabolite in the ESI source [27]. The 259 
conventional strategy of spiking a blank matrix sample with a compound standard was again not 260 
possible as completely blank matrices were not available for these metabolites. The applied SIL-261 
based method was a modified version of the conventional method to evaluate matrix effect 262 
described by Matuszewski et al. [32]. The observed matrix effect was rendered insignificant by 263 
utilizing matrix-matched external calibration.  264 
 265 
2.8 Application  266 
To determine the application range of the method, the relative matrix effect was evaluated by 267 
comparing the response from PP SIL spiked in standard jugular vein plasma with the response in 268 
test plasma samples. Four different sets of samples were assessed. First, plasma from the jugular 269 
vein of four multicatheterized cows was used to investigate within-species variation. Next, plasma 270 
drawn from the portal vein, the hepatic vein, the gastrosplenic vein, and an artery from a 271 
multicatheterized dairy cow to represent different possible sampling sites were examined. Third, 272 
plasma samples from different species (chicken, pig, mink, human, rat) were used for between-273 
species evaluation. Finally, water, urine and milk samples were used to compare different matrices. 274 
The relative recovery determined which of the tested matrices were suitable for the method. For the 275 
same reasons as described previously, SIL replaced compound standards. Water, urine and milk 276 
samples were evaluated in the same manner as plasma samples. 277 
 278 
3. Results and discussion  279 
3.1 Method development  280 
The aim of this study was to develop a quantitative LC-MS/MS analysis and a sample pre-treatment 281 
procedure for the simultaneous analysis of several metabolites of the PP metabolism in blood 282 
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plasma of dairy cows. The chemical properties of the metabolites were polar due to high contents of 283 
–OH, =O and –N groups. Based on their polarity, they were roughly divided into three groups: The 284 
very polar group, containing β-alanine, β-aminoisobutyric acid and β-ureidopropionic acid, were all 285 
small molecules with similar linear polar structures, as well as the also highly polar allantoin, 286 
cytosine and cytidine. The polar group included the majority of the BS, such as adenine, guanine 287 
and uracil, as well as the intermediate DP with more base-like structures, such as uric acid, xanthine 288 
and hypoxanthine.  Finally, the semi polar group comprised the majority of the NS with large but 289 
semi-polar sugar side groups, such as most of the ribonucleosides (2× -OH) and 290 
deoxyribonucleosides (1× -OH). Owing to their very non-polar methyl side groups, thymine and 291 
thymidine were also placed in the semi polar group. The very polar metabolites were poorly 292 
retained on the C18 column with the aqueous solvents and eluted first as expected, offering a longer 293 
retention time of the less polar components.   294 
 295 
3.1.1 Pre-treatment development and evaluation  296 
An effective clean-up procedure is crucial when performing LC-MS/MS analysis as this diminishes 297 
cross-talk [33,34] as well as matrix effects [35] and at the same time enhances both the selectivity 298 
and the sensitivity of the analysis [29]. A novel multi-step approach, consisting of protein 299 
precipitation, ultrafiltration, evaporation under nitrogen flow, and subsequent resolution, able to 300 
purify and to concentrate all of the studied metabolites from bovine plasma simultaneously, in a 301 
simple and efficient manner, was developed and optimized.  302 
Initially, different solvents (acetone, acetonitrile, ethanol, methanol, sulfo-salicylic acid) were tested 303 
for precipitation (data not shown). Ethanol precipitation resulted in the highest recoveries and least 304 
noise when comparing chromatographic responses and this less harmful solvent was therefore 305 
chosen for the procedure. The ultrafiltration step was added as this step caused markedly lower 306 
13 
 
    
levels of background noise. As a consequence of the approximately eight-fold dilution during pre-307 
treatment, evaporation and reconstitution steps were included. Overall this resulted in a 1.4 times 308 
concentration effect. To try to reduce degradation and instability of the samples caused by reactive 309 
oxygen species or enzyme activities during pre-treatment, all centrifugations and incubations were 310 
performed at 4°C and samples, stocks, and solvents etc. were kept at -4°C or on ice. Only during 311 
evaporation were the samples maintained at room temperature. Other types of pre-treatment 312 
methods such as simple dilution (impractical), solid phase extraction (different chemical properties) 313 
[36,37] and accelerated solvent extraction [38] were also investigated (data not shown) but were not 314 
found useful.  315 
The effectiveness of the pre-treatment and the stability of the metabolites during the multiple steps 316 
were evaluated during validation of the method, described in section 3.3, and demonstrated the 317 
ability of this pre-treatment to purify and concentrate all of the targeted PP simultaneously in an 318 
easy and efficient manner without significant losses. To our knowledge, no other publications have 319 
presented a similar and effective pre-treatment procedure, as most other approaches include dilution 320 
of the samples. 321 
 322 
3.1.2 LC-MS/MS procedure  323 
Based on the chemical properties of the targeted metabolites, experiences from similar studies 324 
[14,39], and available equipment, a reversed-phase C18 column known to be able to quantify the 325 
majority of the studied metabolites from urine was applied with an acetic acid buffer/methanol 326 
HPLC solvent system.  327 
To achieve adequate separation and elution order, a series of conditions were modified and 328 
implemented. The composition of the acetic acid buffer and the methanol extraction solvent was 329 
based on the work of Hartmann et al. (2006) [39], and no other types of solvent were tested. Having 330 
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tested several acetic acid buffer to methanol ratios (95%, 90%, 85%, and 80% v/v), assessing peak 331 
separation and shapes, it was concluded that the best separation was accomplished with a 90% v/v 332 
solvent (A) and 50% v/v solvent (B). The chosen injection volume, 5 µL, and flow rate, 200 333 
µL/min, was found by assessing the same parameters, testing first injections of 5, 10, 20 µL and 334 
then flow rates of 100, 200, 300 and 400 µL/min. Concerning the elution gradient, we strived to 335 
make it as short as possible, while still achieving as good a peak separation as possible. Different 336 
elution profiles were tested, with more or less steep gradients. The final profile, described in section 337 
2.5, gave a total run time of 18 min. By adding a small amount of methanol to the otherwise 338 
aqueous solvent (A), and, by keeping the baseline at 5% solvent (B), the solvent mixing became 339 
more smooth and transitions between runs became more stable. A major improvement in precision 340 
between runs was achieved by maintaining the column temperature at 30°C instead of 25°C. An 341 
improvement in the sample stability during the time-consuming analyses was achieved by cooling 342 
the auto-sampler to 4°C. In the end, useful combinations of retention times and peak shapes of each 343 
metabolite were achieved with the parameters described, and the method was therefore adapted and 344 
brought on to further validation.  345 
 346 
3.2 The log-calibration model and quantification range 347 
Calibration curves were prepared by linear regression of log(area) against log(concentration) (log-348 
calibration) and by linear regression in linear units on both axes (linear calibration) to verify the use 349 
of the log-calibration model. Initially, the normality of residuals around the calibration lines were 350 
inspected visually (Q-Q plot) and found to be approximately normal. The CV% for each 351 
concentration level for both the log-calibration and the linear calibration is illustrated in figure 1. A 352 
large group of the PP (panel I) considerably improved their CV% profiles using the log-calibration, 353 
especially in the low ranges. However, a smaller group of PP (panel II) did not benefit from the log 354 
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transformation; and the transformation did not weaken as their CV% profiles either. Exceptions 355 
were with allantoin, β-ureidopropionic acid, cytosine and β-alanine, their CV% at the high end of 356 
their profiles were better without the log-log transformation. Given that quantification at low 357 
concentrations was considered to be most important, these findings validated the use of log-log 358 
transformation in the analysis of all the applied PPs. Performing a lack of fit test, the linearity of the 359 
PP calibration curves were evaluated and expressed by their P-values (Table 4). None of the PP 360 
curves resulted in a significant lack of fit except uridine, which had a very low sensitivity in the 361 
analysis, demonstrating a satisfying log-log regression.  362 
The homogeneity of variance for the different concentration levels is illustrated in Figure 2 and the 363 
quantification ranges (CV<25%) in Table 4. Focusing on the lower concentration range, most of the 364 
PP demonstrated a typical precision profile where the CV% decreased with higher concentration 365 
levels. All purines had acceptable variation levels around the lowest concentration levels except 366 
allantoin, which should not be quantified at concentrations below ~100 µmol/L. The pyrimidine BS 367 
and cytidine and uridine had larger CV%’s with acceptable lower concentration levels from 0.66-368 
5.15 µmol/L. Thymidine and 2’-deoxyuridine demonstrated a very large variation with CV%’s 369 
above 25% over the entire concentration range. In the case of the pyrimidine DP, they were 370 
reasonably stable over their concentration ranges, not counting β-alanine which only had a 371 
CV%<25% at its highest calibrator. The upper part of the quantification range was in all cases the 372 
highest quantified calibrator. 373 
 374 
Figure 1, Figure 2 375 
 376 
3.3 Method validation  377 
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Once the pre-treatment, LC-MS/MS procedure, and calibration model had been set, the 378 
performance characteristics of the method were established by validation with spiked standard 379 
plasma. In terms of quantification purposes, selectivity, stability, precision, recovery, and matrix 380 
effects were evaluated. 381 
The most intensive fragment ion from each precursor ion was selected as the transition ion for 382 
detection and quantification. Positive identification was based on the correlation of retention time 383 
with the standards and the selected precursor/product transition. Less intensive second transitions 384 
were used for confirmation. All metabolites generated single peak shapes. 385 
 386 
3.3.1 Selectivity  387 
A blank sample for selectivity evaluation was not available for these naturally occurring plasma 388 
metabolites. Hence, the presence of chromatographic peaks from standard plasma at the same 389 
retention times as the targeted metabolites could not be excluded; such endogenous peaks would be 390 
expected to be present. Instead, the absence of standard compound/SIL cross-talk contributions was 391 
verified by comparing chromatographic responses for standards and SIL alone and in a mixture 392 
(data not shown). It was important to assess cross-talk contributions, as some of the applied SIL 393 
(Table 3) had less than three mass unit differences (3-8) to the natural metabolite, which is normally 394 
recommended as the lowest mass unit difference for LC-MS/MS analysis [33,34].  395 
 396 
3.3.3 Stability  397 
Good stability was achieved by optimizing the pre-treatment and LC-MS/MS parameters as 398 
described in section 3.1.  Long-term storage stability was tested by comparing chromatographic 399 
profiles of quality control standard plasma on a daily basis. Within-run stability was evaluated by 400 
analyzing a control sample at the beginning and end of each sequence. Long sequence run times 401 
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have been of concern and the within-run stability was consequently also evaluated by performing 402 
ANOVA for measurements made at times 0, 7, 15, 22 and 29 hours, during a 30 hour sequence with 403 
triplicate determinations at each time-point, using either a slope model: yij = intercept + 404 
b*time_hour + εij, or a combined model: yij = intercept + timei + b*time_hour + εij, where yij is the 405 
area measured in the sample at time i, replicate j, and b is the slope of the area change per hour, and 406 
εij is the random error term. Significance of the time effects were tested using an F-test with type 1 407 
sum of squares. Residual mean square error was calculated as the square of the residual variance 408 
estimate and expressed as CV%. The metabolite responses were normalized as usual but the SIL 409 
responses were not since they could not be used to normalize themselves. The results are given in 410 
Table 5.  411 
In general, the combined model resulted in lower CV%’s than the slope model, as the irregular time 412 
effect was also taken into consideration in the combined model. All but a few metabolites 413 
demonstrated very stable profiles over the 30 hour time span with CV%≤10%. Exceptions were 414 
thymidine (136%), 2’-deoxyuridine (46%) and β-alanine (13%), where especially the former two 415 
were found to be unstable. This was probably due to low sensitivities in the analysis. The SILs were 416 
found to be equally or more stable than their corresponding metabolites probably due to their higher 417 
spike concentrations. As expected, thymidine (U-15N2) and β-alanine (U-13C3;15N) had the same 418 
instability issues as their partners. No 2’-deoxyuridine SIL was applied in this analysis. 419 
Surprisingly, the uracil and cytidine SIL had CV%’s above 10%. In the case of uracil (13%), 420 
excessive degradation was avoided by always placing uracil samples in the beginning of a 421 
sequence.  422 
To assess the stability of the calibration curves between run-days, ANOVA was conducted 423 
determining the across-day (intermediate precision) precision (Table 4). Most PP demonstrated a 424 
significant (P<0.05) difference between test days on either curve intercept or slope, or at least a 425 
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tendency (P<0.1). Exceptions were with allantoin, cytosine, uridine, thymidine and 2’-426 
deoxyuridine, all of which revealed reasonably stable curves over test days. These results 427 
demonstrated the need for renewing calibration curves on a daily basis. 428 
 429 
Table 5 430 
 431 
3.3.4 Precision and recovery  432 
To ensure correct quantification and to evaluate analytical precision, within-day and across-day 433 
variation was determined by studying replicate sets of spiked standard plasma samples (n = 8, 434 
samples) on five separate days (m = 5, days). Here, precision was defined as the degree to which 435 
repeated measurements under unchanged conditions showed the same result, expressed as the CV%. 436 
Absolute recoveries were identified by using the same set of spiked standard plasma samples, 437 
comparing the recovered quantified concentrations with the initial spiked concentrations. Since 438 
linearity ranges were short and close to zero, a single, instead of the traditional three, recovery 439 
concentration levels was chosen. Precision and recovery outcomes are given in Table 6. The 440 
obtained results showed very good extraction efficiency and precision. The recoveries were 441 
between 91% and 107%, except for uric acid with a lower recovery of 78%. Also, the low 442 
sensitivity and accompanying instability of cytidine, thymidine and 2’-deoxyuridine was again 443 
highlighted with recoveries of 162%, 121%, and 149%, respectively. In general, the within- and 444 
across-day variations mirrored the recovery results. The exceptions were with allantoin and 445 
cytosine, both of which had good recoveries, 107% and 103%, but exhibited large CV%’s, within-446 
day variation 34% and 21%, and across day variation 49% and 24%, respectively. 447 
 448 
Table 6 449 
 450 
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3.3.5 Absolute matrix effect 451 
It is useful to distinguish between two types of matrix effects: absolute matrix effect, which is the 452 
difference in response between an undiluted solution and a post-extraction spiked sample, and 453 
relative matrix effect (section 3.4), which is the difference between various lots of post-extraction 454 
spiked samples [32]. Matrix effects are very common problems when applying LC-MS/MS analysis 455 
on biological samples [22, 35, 40]. The term describes the effect molecules originating from the 456 
sample matrix can have on the ionization process in the mass spectrometer when co-eluting with the 457 
compound of interest. It theoretically occurs in either the solution or the gaseous phase and the main 458 
cause is a change in droplet solution properties caused by the presence of nonvolatile and less 459 
volatile solutes that change the efficiency of droplet formation and evaporation, which in turn 460 
affects the amount of charged ions in the gas phase that ultimately reach the detector [35]. As the 461 
effect occurs in the ESI source before detection, it is hard to compensate for by mass spectrometry 462 
alone [41,42]. In this analysis, the matrix effect was quantified by comparing the response of SIL in 463 
spiked matrix samples before extraction with the response obtained in water. Matrix effects for all 464 
SILs are illustrated in Figure 3.   465 
Recognizing that the nature of matrix effects is varying and the sensitivity between metabolites are 466 
very different the sizes of the bars are relative indicators of the degree of suppression or 467 
enhancement. Signal enhancement was observed in plasma for almost all metabolites, and only a 468 
few, such as inosine, cytidine, β-alanine and cytosine, had their signals suppressed. These 469 
metabolites did not share any obvious similarities in polarity or structure; however, matrix effects 470 
are known to be very compound-dependent [22]. In contrast to the signal enhancement generally 471 
encountered in plasma, in urine all metabolite signals were suppressed. This demonstrates the 472 
different matrix effects a given component experience when present in different matrices in LC-473 
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MS/MS analysis. In milk, only the purines had a common pattern, i.e., signal suppression, and the 474 
remaining metabolites were neither suppressed nor enhanced. 475 
Matrix effects can vary between measurements, hence, it is not possible to test for matrix effects 476 
only once and consider it to be constant [43]. Matrix effects were largely eliminated in the analysis 477 
first of all by making the external calibrators matrix-matched, hence, quantifying calibrators and 478 
sample metabolites under the same conditions, secondly, by implementing a very effective pre-479 
treatment [33, 44], and thirdly, by implementing SIL [22, 42]. Matrix-matching is necessary when 480 
specific SILs are not available for all metabolites [42]. These initiatives compensated quite well for 481 
the signal suppression or enhancement in the plasma samples, thereby achieving accurate 482 
quantification.   483 
 484 
Figure 3 485 
 486 
3.4 Analytical application (relative matrix effect)  487 
This LC-MS/MS analysis was established for quantification of 20 target metabolites of the PP 488 
metabolism in blood plasma samples from multicatheterized cows. Since jugular vein plasma 489 
(representing systemic circulating blood) was used for method development and because 490 
quantification relied on matrix-matched calibration (jugular vein plasma), the relative matrix effect 491 
was evaluated in alternative types of plasma. The relative matrix effect was evaluated by comparing 492 
the response from SIL spiked in standard jugular vein plasma with the response in tested plasma 493 
samples. A relative recovery between 85% and 115% was considered good and between 75% and 494 
125% acceptable, hence, tested samples exerted the same matrix effect on the metabolite as the cow 495 
jugular vein plasma sample. The generosity of 75-125% was due to the small sample size (n = 2 496 
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samples) inevitably resulting in less precision. The PP responses given as recovery (%) are depicted 497 
in Table 7.  498 
First of all, it was confirmed that within-species variation was not an issue with any of the 499 
metabolites examined, except for uridine. Secondly, the results demonstrated that all the examined 500 
metabolites, evaluated in all four plasma types from feeding experiments with multicatheterized 501 
cows with this particular type of cow model, could appropriately be quantified with the developed 502 
LC-MS/MS method. Only xanthine (67%), uridine (135%/148%/127%) and thymidine (132%) 503 
displayed recoveries outside the acceptable range of 75-125% and especially thymidine will be hard 504 
to quantify with this method due to other issues anyway. Surprisingly, the between-species range 505 
was very broad and most metabolites could be evaluated in plasma from other species tested with a 506 
few exceptions. Further confirmed was also the results from section 3.3.5, concluding that matrix 507 
effects varied significantly between different types of matrices such as water, plasma, urine and 508 
milk. Hence, it is necessary to design, optimize and validate a specific LC-MS/MS method for each 509 
applied matrix.  510 
 511 
Table 7 512 
 513 
4. Conclusions  514 
This work presents the development and validation of a new method for simultaneous and accurate 515 
quantification of 20 targeted metabolites of PP metabolism with different structures and physio-516 
chemical properties in blood plasma from dairy cows. Exceptions were with cytidine, thymidine 517 
and 2’-deoxyuridine, where the method’s sensitivity for these three PP metabolites was so low that 518 
they caused imprecise quantification over the examined concentration ranges. The metabolites were 519 
purified and concentrated using a novel multi-step pre-treatment procedure consisting of protein 520 
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precipitation, ultrafiltration, evaporation under nitrogen flow, and subsequent reconstitution. This 521 
procedure ensured efficient recoveries for most investigated metabolites and efficient removal of 522 
interfering matrix components. The method is selective, sensitive, stable, and precise. The potential 523 
application of the method was demonstrated by evaluating its range of use in different types of 524 
blood plasma from multicatheterized cows, here, only uridine, showed undesirable matrix effects. 525 
The method is adaptable and can be further developed for the quantitative detection of the same 526 
metabolites in other matrices such as urine or milk. 527 
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 653 
Figure captions 654 
Fig. 1. The coefficient of variation (CV%) for each concentration level using linear regression of 655 
area against concentration (linear calibration) and using linear regression of log(area) against 656 
log(concentration) (log-calibration). Panel I present the 13 purines and pyrimidines that 657 
considerably improved their CV% profiles using the log-calibration. Panel II, present the seven 658 
purines and pyrimidines that did not benefit from the log transformation. Abbreviations for the 20 659 
metabolites: Ade, adenine; Gua, guanine; Guo, guanosine; Ino, inosine; dGuo, 2’-deoxyguanosine; 660 
dIno, 2’-deoxyinosine; Xan, xanthine; Hyp, hypoxanthine; Uac, uric acid; All, allantoin; Urd, 661 
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uridine; β-ure, β-ureidopropionic acid; β-ami, β-aminoisobutyric acid; Cyt, cytosine; Thy, thymine; 662 
Ura, uracil; Cyd, Cytidine; Thd, thymidine; dUrd, 2’-deoxyuridine; β-ala, β-alanine. 663 
 664 
Fig. 2. The homogeneity of variance for the different concentration levels of the purine and 665 
pyrimidine calibration curves divided into bases, nucleosides and degradation products (CV%). 666 
Abbreviations for the 20 metabolites: Ade, adenine; Gua, guanine; Guo, guanosine; Ino, inosine; 667 
dGuo, 2’-deoxyguanosine; dIno, 2’-deoxyinosine; Xan, xanthine; Hyp, hypoxanthine; Uac, uric 668 
acid; All, allantoin; Urd, uridine; β-ure, β-ureidopropionic acid; β-ami, β-aminoisobutyric acid; Cyt, 669 
cytosine; Thy, thymine; Ura, uracil; Cyd, Cytidine; Thd, thymidine; dUrd, 2’-deoxyuridine; β-ala, 670 
β-alanine. 671 
 672 
Fig. 3. Matrix effects in plasma, urine and milk expressed as response relative to water (area). 673 
 674 
 675 
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Highlights 
 
• Simultaneous quantification of 20 purines and pyrimidines  
• LC-MS/MS method developed and validated for bovine blood plasma 
• Novel metabolite concentrating pre-treatment  
• Matrix-matched calibration standards and stable isotopically-labelled references 
• The method is simple, sensitive and specific  
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Table 1  
Names, types, empirical formulae and suggestions for fragmentations of the compounds analyzed 
by the LC-MS/MS method 
 
Purines 
 
 
Pyrimidines 
 
 
Name 
 
 
Type 
 
 
Empirical formula 
 
 
Name 
 
 
Type 
 
 
Empirical formula 
 
Adenine 
Frag. 1 Base 
N
N
NH
N
NH2
 
Cytosine 
 Base N
NH
NH2
O  
Guanine 
Frag. 2 Base 
N
NH
NH
N
NH2
O
 
Thymine 
 Base 
NH
NH
O
O
CH3
 
Guanosine 
Frag. 3 NS N
OOH
OH
N
NHN
NH2
O
OH  
Uracil 
 Base 
NH
NH
O
O 
Inosine 
 NS N
OOH
OH
N
NHN
O
OH  
Cytidine 
 NS N
OOH
OH
N
NH2
O
OH  
2’-deoxyguanosine 
Frag. 4 NS N
OOH
OH
N
NHN
NH2
O
 
Uridine 
 NS N
OOH
OH
NH
O
O
OH  
2’-deoxyinosine 
 NS N
OOH
OH
N
NHN
O
 
Thymidine 
Frag. 7 NS N
OOH
OH
NH
O
O
CH3
 
Xanthine 
 
Base
/DP 
NH
NH
N
N
H
O
O
 
2’-deoxyuridine 
 NS N
OOH
OH
NH
O
O
 
Hypoxanthine 
Frag. 5 
Base
/DP NH
N
N
N
H
O
 
β-alanine 
Frag. 8 DP 
NH2
O
OH  
Uric acid 
 DP 
N
H
NH
NH
N
H
O
O
O
 
β-ureidopropionic 
acid  
 
DP 
NH
O
OH NH2
O
 
Allantoin 
Frag. 6 DP 
NH
NH2
NH
N
H
O
O
O
 
β-aminoisobutyric 
acid  
 
DP 
NH2
O
OH
 
NS, nucleoside; DP, degradation product. 
Illustrated with lines are the eight types of suggested metabolite fragmentations. 
 
 
 
 
Table 2  
The 20 metabolites were divided into five groups and run according to ESI -/+ mode and structure  
 
Metabolite group and  ESI mode -/+ 
 
 
 
Group 1:Base/DP (ESI -) 
 
Group 2:Base/DP (ESI +) 
 
Group 3:NS (ESI -) 
 
Group 4:Uracil (ESI +) 
Adenine (1) 
Guanine (2) 
Xanthine (3) 
Allantoin (4) 
(Uric acid 1,3-15N2) (5)  
 
 
Group 5:Uric acid (ESI -) 
Uric acid (5) 
Cytosine (6) 
Thymine (7) 
Hypoxanthine (8) 
β-alanine (9) 
β-ureidopropionic acid (10) 
β-aminoisobutyric acid (11) 
 
Guanosine (12) 
Cytidine (13) 
Uridine (14) 
Inosine (15) 
Thymidine (16) 
2’-deoxyguanosine (17) 
2’-deoxyinosine (18) 
2’-deoxyuridine (19) 
Uracil (20) 
 
 
DP, degradation product; NS, nucleoside. 
Plasma samples and standard plasma for quantification and external calibration of uracil and uric acid were diluted 25% and 5% v/v, respectively, in water. A group 5 
chromatographic profile (uric acid) is not illustrated in the table since uric acid (1,3-15N2) can be observed with group 1 (same peak, same shape, same RT). 
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Table 3  
Transition reactions monitored by LC-MS/MS, cone voltages and collision energy for the metabolite/stable isotopically-labelled reference 
compound (SIL) analyzed, and suggested corresponding fragments lost 
 
Metabolite/SIL 
 
Mw 
(g/mol) 
 
 
Retention time 
(min) 
 
 
Precursor ion 
(m/z) 
 
 
Cone voltage 
(V)  
 
 
Product ion 
(m/z) 
 
 
Collision energy 
(eV)  
 
 
Neutral loss 
(NL) 
 
 
Fragmentation 1-8  
 
 
 
Purines 
    
     
Adenine/ 
Adenine (8-13C) 
135.13
136.12 3.81 
134 
135  - 
35 
36 
107 
108 
16 
17 27 - HCN 1 
Guanine/ 
Guanine (8-13C,7,9-15N2) 
151.13 
154.11 3.86 
150  
153 - 
28 
30 
133 
136 
13 
13 17 - NH3 2 
Guanosine/ 
Guanosine (U-13C10;U-15N5) 
283.24 
298.13 6.18 
282  
297 - 
33 
33 
150 
160 
19 
20 
132 
137 - deoxyribose 3 
Inosine/ 
Inosine (U-15N4) 
268.23 
272.20 5.81 
267 
271  - 
26 
26 
135 
139 
20 
20 132 - deoxyribose 3 
2’-deoxyguanosine/ 
2’-deoxyguanosine (U-15N5) 
267.24 
272.17 7.31 
266  
271 - 
26 
28 
150 
155 
19 
20 116 - ribose 4 
2’-deoxyinosine/  
2’-deoxyguanosine (U-15N5)a 
252.23 
- 
6.74 
- 
251  
- 
- 
 
27 
- 
135 
- 
20 
- 
116 - ribose 4 
Xanthine/ 
Xanthine (1,3-15N2) 
152.11 
154.10 5.18 
151 
153  - 
29 
31 
108 
109 
16 
16 
43 
44 - HNCO 5 
Hypoxanthine/ 
Hypoxanthine (15N4) 
136.11 
140.09 4.56 
135  
141 + 
34 
34 
92 
113 
16 
19 
43 
27 
- HNCO 
- HCN 
5 
1 
Uric acid/ 
Uric acid (1,3-15N2) 
168.11 
170.10 4.28 
167 
169  - 
26 
29 
124 
125 
16 
14 
43 
44 - HNCO 5 
Allantoin/  
Uric acid (1,3-15N2)a 
158.12 
- 
3.05 
- 
157  
- 
- 
 
16 
- 
97 
- 
16 
- 
60 - HNCONH2 6 
 
Pyrimidines 
        
Cytosine/ 
Cytosine (2,4-13C2;15N3) 
111.95 
116.08 2.91 
112 
117 + 
29 
30 
95 
99 
20 
19 
17 
18 - NH3 2 
Thymine/ 
Thymine (15N2) 
126.11 
128.10 6.21 
127  
129 + 
27 
27 
110 
111 
7 
16 
17 
18 - NH3 2 
Uracil/ 
Uracil (U-13C4;U-15N2) 
112.09 
118.04 3.97 
113 
119  + 
26 
27 
96 
101 
7 
16 
17 
18 - NH3 2 
Cytidine/ 
Cytidine (U-13C9;U-15N3) 
243.22 
255.13 3.19 
242 
254  - 
23 
21 
109 
116 
14 
15 
133 
138 - deoxyribose 3 
Uridine/ 
Uridine (U-13C9;U-15N2) 
244.20 
255.12 4.50 
243 
254  - 
23 
28 
110 
116 
15 
16 
133 
138 - deoxyribose 3 
Thymidine/ 
Thymidine (U-15N2) 
242.23 
244.22 8.52 
241  
243 - 
25 
26 
151 
153 
12 
11 90 - rearrangement 7 
2’-deoxyuridine/ 
2’-deoxyguanosine (U-15N5)a 
228.20 
- 
5.34 
- 
227  
- - 
22 
- 
184 
- 
12 
- 
43 - HNCO 5 
β-alanine/ 
β-alanine (U-13C3;15N) 
89.09 
93.07 2.91 
90  
94 + 
13 
14 
72 
76 
10 
7 18 - H2O 8 
β-ureidopropionic acid/  
β-alanine (U-13C3;15N) a 
132.12 
- 
3.77 
- 
133  
- 
+ 11 
- 
115 
- 
10 
- 
18 - H2O 8 
β-aminoisobutyric acid/ 
β-alanine (U-13C3;15N) a 
103.12 
- 
2.98 
- 
104  
- 
+ 13 
- 
86 
- 
10 
- 
18 - H2O 8 
           
SIL, stable isotopically-labelled reference compound. 
All metabolites had a specific retention time and generated single peak shapes. 
a This SIL was selected as the most suitable according to structure, retention time, fragmentation pattern and metabolite group.  
 
Table 4  
Concentration level, calibration range, lack-of fit, quantification range and precision of the metabolite calibration curves 
 
Metabolite 
   
Rangea 
  
Linearity 
  
Precision (test-day)d 
 
 
Type 
 
  
Concentration levels 
 
 
Calibration range 
(µmol/L) 
 
  
Lack of fitb 
P-value 
 
Quantification rangec 
(µmol/L) 
 
  
Intercept 
P-value  
 
 
Slope 
P-value  
 
Purines 
        
 
  
Adenine  Base  7 0-5.0  0.84 0.08-5.0  0.096 0.059 
Guanine  Base  7 0-5.0  0.15 0.08-5.0  0.041 0.994 
Guanosine  NS  7 0-5.0  0.79 0.16-5.0  0.071 0.003 
Inosine  NS  7 0-5.0  0.23 0.08-5.0  0.013 0.004 
2’-deoxyguanosine  NS  7 0-5.0  0.06 0.08-5.0  0.029 0.294 
2’-deoxyinosine  NS  7 0-5.0  0.92 0.16-5.0  <0.001 0.021 
Xanthine Base/DP  7 0-5.0  0.67 0.16-5.0  0.087 0.006 
Hypoxanthine  Base/DP  7 0-5.0  0.40 0.08-5.0  0.009 <.001 
Uric acid DP  7 0-200   0.99 3.15-200  <.001 0.003 
Allantoin DP  4  15-500   0.64 124-500  0.427 0.897 
 
Pyrimidines 
        
 
  
Cytosine  Base  7 0-7.5  0.84 1.92-7.5  0.566 0.274 
Thymine Base  7 0-5.0  0.68 1.27-5.0  0.035 0.030 
Uracil  Base  7 0-5.0  0.88 0.66-5.0  <0.001 0.042 
Cytidine NS  7 0-5.0  0.70 5.15-5.0  0.086 0.670 
Uridine NS  7 0-7.5   0.02 1.91-7.5  0.286 0.480 
Thymidine NS  7 0-5.0  0.48 - e  0.741 0.599 
2’-deoxyuridine NS  7 0-5.0  0.35 - e  0.151 0.309 
β-alanine DP  7 0.25-13  0.59 13-13  <0.001 0.070 
β-ureidopropionic acid DP  7 0-75   0.87 4.67-75  0.003 0.283 
β-aminoisobutyric acid DP  7 0-5.0  0.29 0.31-5.0  0.026 0.571 
           
NS, nucleoside; DP, degradation product.  
Only four curves were available for uric acid and β-ureidopropionic acid. In the case of allantoin, the three lower concentration levels were excluded to better fit the 
concentration range of actual samples. For uridine, one observation in one curve was considered an outlier following visual inspection and was rejected. 
a External calibration was performed with seven concentrations of metabolite on five separate days (n = 5, days), except for allantoin where only four concentration 
levels were available. The ranges where chosen according to concentration ranges in actual samples. 
b Lack of fit hypothesis test to validate the linearity of the calibration curves expressed by their P-values (n = 5, curves). P < 0.05 was considered significant. 
c The quantification range was set to the lowest and highest quantified concentration giving an acceptable CV%<25% (see Figure 2).   
d The intermediate precision of the calibration curves (intercepts and slopes as interactions with test day) expressed by their P-values (n = 5, days). P < 0.05 was 
considered significant, P < 0.1 a tendency.  
e Value is above the highest calibrator concentration. 
 
Table 5  
Stability of each metabolite/stable isotopically-labelled reference compound during a 30 hour sequence 
 
Metabolite 
 
Concentration level 
(µmol/L) 
 
 
Slope model 
(CV%) 
 
 
Combined  model 
(CV%) 
 
  
Corresponding SIL 
 
 
Concentration level 
(µmol/L) 
 
 
Slope model 
(CV%) 
 
 
Combined  model 
(CV%) 
 
 
Purines 
  
 
   
Purines 
  
 
 
Adenine 4 9 4  Adenine (8-13C) 7 8 5 
Guanine 4 11 8  Guanine (8-13C,7,9-15N2) 7 9 5 
Guanosine 4 12 7  Guanosine (U-13C10;U-15N5) 7 8 3 
Inosine 4 11 2  Inosine (U-15N4) 7 11 2 
2’-deoxyguanosine 4 14 6  2’-deoxyguanosine (U-15N5) 7 11 3 
2’-deoxyinosine 4 11 5  2’-deoxyguanosine (U-15N5)  - d  - d - d 
Xanthine 4 6 4  Xanthine (1,3-15N2) 7 9 6 
Hypoxanthine 4 12 2  Hypoxanthine (15N4) 7 12 7 
Uric acid 4 12 6  Uric acid (1,3-15N2) 35 9 3 
Allantoin 40 10 7  Uric acid (1,3-15N2)  35 10 7 
 
Pyrimidines 
 
 
   
Pyrimidines   
 
Cytosine 4 26 3  Cytosine (2,4-13C2;15N3) 14 9 9 
Thymine 7 18 10  Thymine (15N2) 7 11 8 
Uracil  4 18 6  Uracil (U-13C4;U-15N2) 14 16 13 
Cytidine 4 11 9  Cytidine (U-13C9;U-15N3) 7 16 12 
Uridine 4  11 4  Uridine (U-13C9;U-15N2) 14 15 9 
Thymidine 7 136 136  Thymidine (U-15N2) 40 18 13 
2’-deoxyuridine 7 46 46  2’-deoxyguanosine (U-15N5)  -a -a -a 
β-alanine 7  16 13  β-alanine (U-13C3;15N) 28 9 6 
β-ureidopropionic acid  7 10 2  β-alanine (U-13C3;15N)  -a  -a -a 
β-aminoisobutyric acid 7 7 5  β-alanine (U-13C3;15N)  -a  -a -a 
         
SIL, stable isotopically-labelled reference compound. 
An appropriate concentration level was chosen for each metabolite/SIL according to their sensitivity in the analysis. The stability (significance of time) of each 
metabolite/SIL was expressed by their CV% using either a slope- or a combined model. The data handling was conducted with metabolite responses in area units. If the 
CV% ≤ 10% the stability was considered acceptable over time.      
a SIL used for more than one metabolite. 
Table 6  
The recovery and within- and across-day variation of each metabolite investigated 
 
Metabolite 
 
Concentration level 
(µmol/L) 
 
  
Concentrationa 
(µmol/L) 
 
 
Recoveryb 
(%) 
 
  
Within-day variationc 
(CV%)  
 
 
Across-day variationd 
(CV%)  
 
Purines 
  
 
    
Adenine 4.17  4.33 104  2 5 
Guanine 4.13  3.77 91  2 4 
Guanosine 4.15  4.13 100  4 12 
Inosine 4.18  4.10 98  2 9 
2’-deoxyguanosine 4.15  4.27 103  4 7 
2’-deoxyinosine 4.11  4.23 103  2 8 
Xanthine 4.12  4.39 106  3 9 
Hypoxanthine 4.11  4.07 99  1 6 
Uric acid 4.08   4.38 78  16 55 
Allantoin 41.44   45 107  34 49 
 
Pyrimidines 
  
 
    
Cytosine 4.13  4,24 103  21 24 
Thymine 6.86  6.72 98  4 15 
Uracil  4.11  4.33 105  5 4 
Cytidine 4.16  6.75 162  18 24 
Uridine c 4.12   3.89 94  7 12 
Thymidine 6.90  8.35 121  23 21 
2’-deoxyuridine 6.86   10 149  33 37 
β-alanine 6.86  7.21 105  12 5 
β-ureidopropionic acid 6.91   6.30 91  14 13 
β-aminoisobutyric acid 6.83  6.86 100  6 7 
        
Only four curves were available for uric acid and β-ureidopropionic acid. In the case of allantoin, the three lower concentration levels were excluded to better fit the 
concentration range of actual samples. For uridine, one observation in one curve was considered an outlier following visual inspection and was rejected. An appropriate 
concentration level was chosen for each metabolite according to the metabolites sensitivity in the analysis. 
a Recovered quantified concentration. 
b The recovery (%) was calculated as: (mean recovery concentration/mean spiked concentration) × 100 (n = 8, samples). Recovery (%) was an average of recoveries 
obtained over five days (m = 5, days). 
c The within-day variation (n = 8, samples) expressed as CV%. 
d The across-day variation (m = 5, days) expressed as CV%. 
 
Table 7  
Comparison of the response from the metabolites (stable isotopically-labelled reference compounds) spiked in standard jugular vein plasma 
with the response obtained in tested plasma samples from four other cows, four other blood vessels, five other animal species and three 
other matrices, to evaluate relative matrix effect and the application range of the method 
 
SIL 
 
  
Four cows 
  
Four vessels 
 
  
Five species 
 
  
Three matrices 
  
1 
 
 
2 
 
3 
 
4 
  
P 
 
 
H 
 
R 
 
A 
  
C 
 
P 
 
M 
 
H 
 
R 
  
W 
 
U 
 
M 
 
Purines 
                    
Adenine (8-13C)  101 102 106 101  99 93 94 83  84 87 71 116 91  88 47 58 
Guanine (8-13C,7,9-15N2)  94 91 106 96  92 88 87 79  74 86 67 106 36  94 54 54 
Guanosine (U-13C10;U-15N5)  110 98 99 103  94 115 122 119  110 115 111 112 120  105 93 77 
Inosine (U-15N4)  113 97 102 101  96 116 121 114  110 114 114 115 121  107 83 68 
2’-deoxyguanosine (U-15N5)  110 101 103 105  95 117 121 107  109 116 117 114 123  99 62 2 
Xanthine (1,3-15N2)  88 86 96 93  85 76 77 67  66 76 66 117 78  97 64 67 
Hypoxanthine (15N4)  103 106 101 105  105 103 108 104  103 108 107 114 90  45 13 116 
Uric acid (1,3-15N2)  97 86 107 97  111 112 107 98  100 99 60 102 95  71 68 110 
 
Pyrimidines 
                    
Cytosine (2,4-13C2;15N3)  95 115 100 107  106 116 104 110  90 82 32 138 98  579 43 999 
Thymine (15N2)  97 96 98 100  100 98 101 101  93 106 98 102 97  98 79 95 
Uracil (U-13C4;U-15N2)  104 93 106 101  101 102 103 105  94 106 97 104 106  88 81 100 
Cytidine (U-13C9;U-15N3)  97 83 96 96  95 122 109 104  124 116 99 108 99  170 30 48 
Uridine (U-13C9;U-15N2)  117 107 101 141  98 135 148 127  62 176 87 80 105  35 14 32 
Thymidine (U-15N2)  102 106 98 112  108 125 132 118  126 118 135 123 126  95 72 102 
β-alanine (U-13C3;15N)  105 105 104 101  110 98 107 107  90 96 77 112 99  357 42 149 
                     
1, cow 1; 2, cow 2; 3, cow 3; 4, cow 4; P, portal hepatic vein; H, hepatic vein; G, gastrosplenic vein; A, artery; C, chicken; P, pig; M, mink; H, human; R, rat; W, 
water; U, urine; M, milk.  
The relative recovery was calculated as: (tested sample(area) - jugular(area)) x 100 (n = 2, samples). A relative recovery between 85% and 115% was considered good 
and between 75% and 125% was considered acceptable. Shaded areas show recoveries not fulfilling these criteria.  
 
